<DrugInformationSummary id="CDR0000562503"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about ibritumomab tiuxetan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan">Ibritumomab Tiuxetan</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000043080">ibritumomab tiuxetan</TerminologyLink><GlossaryLink ref="CDR0000574728">ibritumomab tiuxetan</GlossaryLink><USBrandNames><USBrandName>Zevalin</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>ih-brih-TOO-moh-mab ty-UK-seh-tan</TermPronunciation><MediaLink ref="CDR0000721009" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000721010" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf29429-bf8e-4cce-bd12-1de56853fc5b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Ibritumomab Tiuxetan</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf29429-bf8e-4cce-bd12-1de56853fc5b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Ibritumomab tiuxetan is approved to treat:</Para><ItemizedList Style="bullet" id="_5"><ListItem><Strong><GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell</GlossaryTermRef>  <GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular non-Hodgkin lymphoma</GlossaryTermRef></Strong>. It is used in adults:<ItemizedList Style="bullet" id="_6"><ListItem>With <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000045757" dictionary="Cancer.gov" audience="Patient">low-grade</GlossaryTermRef> disease.</ListItem><ListItem>Who are having a <GlossaryTermRef href="CDR0000045652" dictionary="Cancer.gov" audience="Patient">complete</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045819" dictionary="Cancer.gov" audience="Patient">partial response</GlossaryTermRef> to <GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line</GlossaryTermRef> <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.</ListItem></ItemizedList> </ListItem></ItemizedList><Para id="_3">Ibritumomab tiuxetan is  also being studied in the treatment of other types of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.</Para>                          
 </Section><Section id="_About"><Title>More About Ibritumomab Tiuxetan</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/43080">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a609012.html">Ibritumomab Tiuxetan</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C29981">Find Clinical Trials for Ibritumomab Tiuxetan</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2008-02-26</DateFirstPublished><DateLastModified>2019-10-18</DateLastModified></DrugInformationSummary>
